GlaxoSmithkline Pharmaceuticals Limited Stock Forecast
GlaxoSmithkline Pharmaceuticals Limited stock downgraded from Strong Buy Candidate to Buy Candidate after Friday trading session.
(Updated on Jun 14, 2024)
The GlaxoSmithkline Pharmaceuticals Limited stock price fell by -1.70% on the last day (Friday, 14th Jun 2024) from ₹2,700.70 to ₹2,654.85. During the last trading day the stock fluctuated 4.55% from a day low at ₹2,639.95 to a day high of ₹2,760.00. The price has been going up and down for this period, and there has been a 1.36% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -58 thousand shares and in total, 124 thousand shares were bought and sold for approximately ₹328.49 million.
The stock lies in the upper part of a wide and strong rising trend in the short term, and this may normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break-up at the top trend line at ₹2,712.98 will firstly indicate a stronger rate of rising. Given the current short-term trend, the stock is expected to rise 39.01% during the next 3 months and, with a 90% probability hold a price between ₹3,140.59 and ₹3,771.25 at the end of this 3-month period.
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
GLAXO.NS Signals & Forecast
The GlaxoSmithkline Pharmaceuticals Limited stock holds buy signals from both short and long-term Moving Averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at ₹2,601.50 and ₹2,311.05. A breakdown below any of these levels will issue sell signals. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Thursday, June 13, 2024, and so far it has fallen -1.70%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.
Support, Risk & Stop-loss for GlaxoSmithkline Pharmaceuticals Limited stock
On the downside, the stock finds support just below today's level from accumulated volume at ₹2,480.50 and ₹2,473.55. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, GlaxoSmithkline Pharmaceuticals Limited finds support just below today's level at ₹2,480.50. If this is broken, then the next support from accumulated volume will be at ₹2,473.55 and ₹2,287.00.
This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved ₹120.05 between high and low, or 4.55%. For the last week, the stock has had daily average volatility of 3.85%.
Our recommended stop-loss: ₹2,545.80 (-4.11%) (This stock has medium daily movements and this gives medium risk. There is a sell signal from a pivot top found 8 days ago.)
Trading Expectations (GLAXO.NS) For The Upcoming Trading Day Of Tuesday 18th
For the upcoming trading day on Tuesday, 18th we expect GlaxoSmithkline Pharmaceuticals Limited to open at ₹2,684.93, and during the day (based on 14 day Average True Range), to move between ₹2,546.43 and ₹2,763.27, which gives a possible trading interval of +/-₹108.42 (+/-4.08%) up or down from last closing price. If GlaxoSmithkline Pharmaceuticals Limited takes out the full calculated possible swing range there will be an estimated 8.17% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at ₹2,655.75 (0.03%) than the support at ₹2,480.50 (6.57%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is GlaxoSmithkline Pharmaceuticals Limited stock A Buy?
Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for GlaxoSmithkline Pharmaceuticals Limited stock to perform well in the short-term. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Strong Buy to a Buy candidate.
Current score: 3.155 Buy Candidate Downgraded
Predicted Opening Price for GlaxoSmithkline Pharmaceuticals Limited of Tuesday, June 18, 2024
| Fair opening price June 18, 2024 | Current price |
|---|---|
| ₹2,684.93 ( 1.13%) | ₹2,654.85 |
The predicted opening price is based on yesterday's movements between high, low, and closing price.
Trading levels for GLAXO.NS
Fibonacci Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 2,804.98 | 5.66% |
| R2 | 2,759.12 | 3.93% |
| R1 | 2,730.79 | 2.86% |
| Price | 2,654.85 | |
| S1 | 2,639.07 | -0.594% |
| S2 | 2,610.74 | -1.66% |
| S3 | 2,564.88 | -3.39% |
Accumulated Volume Support & Resistance Levels
| Level | Price | |
|---|---|---|
| R3 | 0 | - |
| R2 | 2,700.70 | 1.73% |
| R1 | 2,655.75 | 0.0339% |
| Price | 2,654.85 | |
| S1 | 2,480.50 | -6.57% |
| S2 | 2,473.55 | -6.83% |
| S3 | 2,287.00 | -13.86% |
GLAXO Dividend Payout History
| # | Ex-Date | Pay Date | Amount | Yield | |
|---|---|---|---|---|---|
| 1 | May 31, 2024 | May 31, 2024 | Jul 28, 2024 | ₹32.00 | 1.21% |
| 2 | Jun 30, 2023 | Jun 30, 2023 | Jun 30, 2023 | ₹32.00 | 2.25% |
| 3 | Jul 07, 2022 | Jul 07, 2022 | Jul 07, 2022 | ₹60.00 | 3.99% |
| 4 | Jul 19, 2021 | Jul 19, 2021 | Jul 19, 2021 | ₹30.00 | 1.87% |
| 5 | May 18, 2020 | Jul 17, 2020 | Jul 27, 2020 | ₹20.00 | 1.37% |
FAQ
Click here for our free guide on how to buy GlaxoSmithkline Pharmaceuticals Limited Stock.
